Syncom Formulations (India) Limited (SYNCOMF.NS)
INR 17.4
(3.82%)
INR 17.4
(3.82%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 559.5 Million INR | -19.18% |
| 2022 | 825.58 Million INR | 16.32% |
| 2021 | 709.74 Million INR | -1.76% |
| 2020 | 722.43 Million INR | 68.69% |
| 2019 | 428.26 Million INR | 4.76% |
| 2018 | 408.78 Million INR | 1.24% |
| 2017 | 403.78 Million INR | -22.97% |
| 2016 | 524.21 Million INR | 9.62% |
| 2015 | 478.21 Million INR | -16.69% |
| 2014 | 574.01 Million INR | 24.02% |
| 2013 | 462.84 Million INR | 23.72% |
| 2012 | 374.11 Million INR | 106.33% |
| 2011 | 181.31 Million INR | 514.46% |
| 2010 | 29.5 Million INR | -67.98% |
| 2009 | 92.15 Million INR | 37.06% |
| 2008 | 67.23 Million INR | -0.35% |
| 2007 | 67.47 Million INR | 39.37% |
| 2006 | 48.41 Million INR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 217.92 Million INR | -0.42% |
| 2023 Q1 | 242.86 Million INR | 2.86% |
| 2023 FY | 667.26 Million INR | -19.18% |
| 2023 Q4 | 218.85 Million INR | 51.68% |
| 2023 Q3 | 144.28 Million INR | -41.67% |
| 2023 Q2 | 247.34 Million INR | 1.85% |
| 2022 Q3 | 226.1 Million INR | 24.5% |
| 2022 FY | 825.58 Million INR | 16.32% |
| 2022 Q1 | 181.76 Million INR | 39.95% |
| 2022 Q2 | 181.61 Million INR | -0.08% |
| 2022 Q4 | 236.1 Million INR | 4.43% |
| 2021 Q4 | 129.87 Million INR | -32.31% |
| 2021 Q1 | 182.35 Million INR | 23.03% |
| 2021 Q2 | 205.63 Million INR | 12.77% |
| 2021 FY | 709.74 Million INR | -1.76% |
| 2021 Q3 | 191.87 Million INR | -6.69% |
| 2020 Q2 | 211.7 Million INR | 96.6% |
| 2020 FY | 722.43 Million INR | 68.69% |
| 2020 Q4 | 148.21 Million INR | -41.84% |
| 2020 Q3 | 254.82 Million INR | 20.36% |
| 2020 Q1 | 107.68 Million INR | 749.84% |
| 2019 FY | 428.26 Million INR | 4.76% |
| 2019 Q4 | -16.57 Million INR | -111.9% |
| 2019 Q3 | 139.29 Million INR | -16.04% |
| 2019 Q2 | 165.91 Million INR | 18.84% |
| 2019 Q1 | 139.62 Million INR | 493.8% |
| 2018 FY | 408.78 Million INR | 1.24% |
| 2018 Q4 | 23.51 Million INR | -83.07% |
| 2018 Q3 | 138.85 Million INR | -5.18% |
| 2018 Q2 | 146.44 Million INR | 46.51% |
| 2018 Q1 | 99.95 Million INR | -11.02% |
| 2017 Q1 | 123.25 Million INR | -20.25% |
| 2017 FY | 403.78 Million INR | -22.97% |
| 2017 Q4 | 112.33 Million INR | -15.68% |
| 2017 Q3 | 133.22 Million INR | 4.08% |
| 2017 Q2 | 128 Million INR | 3.86% |
| 2016 FY | 524.21 Million INR | 9.62% |
| 2016 Q4 | 154.54 Million INR | 0.0% |
| 2016 Q1 | 135.76 Million INR | 61.35% |
| 2015 Q4 | 84.14 Million INR | -32.65% |
| 2015 Q3 | 124.92 Million INR | -13.4% |
| 2015 Q2 | 144.25 Million INR | 15.5% |
| 2015 FY | 478.21 Million INR | -16.69% |
| 2015 Q1 | 124.89 Million INR | -18.58% |
| 2014 Q4 | 153.39 Million INR | -1.52% |
| 2014 Q3 | 155.76 Million INR | 1.52% |
| 2014 Q2 | 153.43 Million INR | 37.71% |
| 2014 Q1 | 111.41 Million INR | 15.44% |
| 2014 FY | 574.01 Million INR | 24.02% |
| 2013 Q1 | 106.32 Million INR | -54.05% |
| 2013 Q4 | 96.51 Million INR | -25.44% |
| 2013 Q3 | 129.45 Million INR | -0.84% |
| 2013 Q2 | 130.54 Million INR | 22.78% |
| 2013 FY | 462.84 Million INR | 23.72% |
| 2012 Q3 | 58.65 Million INR | 0.93% |
| 2012 Q4 | 231.38 Million INR | 294.47% |
| 2012 FY | 374.11 Million INR | 106.33% |
| 2012 Q1 | 25.95 Million INR | 0.0% |
| 2012 Q2 | 58.11 Million INR | 123.96% |
| 2011 FY | 181.31 Million INR | 514.46% |
| 2010 FY | 29.5 Million INR | -67.98% |
| 2009 FY | 92.15 Million INR | 37.06% |
| 2008 FY | 67.23 Million INR | -0.35% |
| 2007 FY | 67.47 Million INR | 39.37% |
| 2006 FY | 48.41 Million INR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Hester Biosciences Limited | 1.27 Billion INR | 56.071% |
| RPG Life Sciences Limited | 2.48 Billion INR | 77.467% |
| Suven Pharmaceuticals Limited | 4.12 Billion INR | 86.431% |
| Ipca Laboratories Limited | 48.58 Billion INR | 98.848% |
| Aarti Drugs Limited | 8.31 Billion INR | 93.272% |
| Aarti Pharmalabs Limited | 5.83 Billion INR | 90.405% |
| Albert David Limited | 1.4 Billion INR | 60.265% |
| Alembic Limited | 1 Billion INR | 44.056% |
| Alkem Laboratories Limited | 52.29 Billion INR | 98.93% |
| Alembic Pharmaceuticals Limited | 26.78 Billion INR | 97.911% |
| Bafna Pharmaceuticals Limited | 452.15 Million INR | -23.742% |
| Bajaj HealthCare Limited | 1.47 Billion INR | 61.985% |
| Biofil Chemicals and Pharmaceuticals Limited | 12.54 Million INR | -4359.968% |
| Brooks Laboratories Limited | 65.62 Million INR | -752.641% |
| Eris Lifesciences Limited | 10.42 Billion INR | 94.634% |
| FDC Limited | 6.58 Billion INR | 91.505% |
| Glenmark Life Sciences Limited | 12.43 Billion INR | 95.5% |
| Gufic Biosciences Limited | 4.07 Billion INR | 86.266% |
| Hikal Limited | 5.95 Billion INR | 90.609% |
| Ind-Swift Laboratories Limited | 4.13 Billion INR | 86.463% |
| Ind-Swift Limited | 2.17 Billion INR | 74.246% |
| Innova Captab Limited | 3.46 Billion INR | 83.85% |
| IOL Chemicals and Pharmaceuticals Limited | 4.71 Billion INR | 88.144% |
| Jagsonpal Pharmaceuticals Limited | 652.59 Million INR | 14.264% |
| Jubilant Pharmova Limited | 19.64 Billion INR | 97.152% |
| Kilitch Drugs (India) Limited | 620.47 Million INR | 9.827% |
| Laurus Labs Limited | 15.44 Billion INR | 96.378% |
| Lincoln Pharmaceuticals Limited | 1.88 Billion INR | 70.347% |
| Lupin Limited | 125.09 Billion INR | 99.553% |
| Mangalam Drugs & Organics Limited | 691.19 Million INR | 19.053% |
| Medico Remedies Limited | 262.14 Million INR | -113.433% |
| Morepen Laboratories Limited | 6.16 Billion INR | 90.919% |
| Nectar Lifesciences Limited | 4.82 Billion INR | 88.4% |
| Orchid Pharma Limited | 2.32 Billion INR | 75.887% |
| Procter & Gamble Health Limited | 5.78 Billion INR | 90.322% |
| Sigachi Industries Limited | 2 Billion INR | 72.057% |
| Solara Active Pharma Sciences Limited | -1.65 Billion INR | 133.788% |
| Sun Pharmaceutical Industries Limited | 258.48 Billion INR | 99.784% |
| Themis Medicare Limited | 2.42 Billion INR | 76.88% |
| Unichem Laboratories Limited | 4.86 Billion INR | 88.499% |
| Vaishali Pharma Limited | 90.32 Million INR | -519.447% |
| Venus Remedies Limited | 2.18 Billion INR | 74.365% |
| Wanbury Limited | 1.73 Billion INR | 67.671% |
| Windlas Biotech Limited | 1.33 Billion INR | 58.209% |
| ZIM Laboratories Limited | 1.26 Billion INR | 55.869% |
| Sakar Healthcare Limited | 699.58 Million INR | 20.024% |
| Aurobindo Pharma Limited | 109.54 Billion INR | 99.489% |
| Divi's Laboratories Limited | 32.44 Billion INR | 98.275% |
| AstraZeneca Pharma India Limited | 6.22 Billion INR | 91.009% |
| Mankind Pharma Limited | 42.19 Billion INR | 98.674% |
| Sequent Scientific Limited | 2.97 Billion INR | 81.217% |
| Neuland Laboratories Limited | 8.24 Billion INR | 93.216% |
| J. B. Chemicals & Pharmaceuticals Limited | 15.25 Billion INR | 96.333% |
| Glenmark Pharmaceuticals Limited | 69.34 Billion INR | 99.193% |
| Zydus Lifesciences Limited | 125.21 Billion INR | 99.553% |
| Amrutanjan Health Care Limited | 2.09 Billion INR | 73.281% |
| Wockhardt Limited | 7.72 Billion INR | 92.753% |
| Bal Pharma Limited | 770.19 Million INR | 27.356% |
| Dr. Reddy's Laboratories Limited | 163.6 Billion INR | 99.658% |
| Bliss GVS Pharma Limited | 3.69 Billion INR | 84.86% |
| Par Drugs and Chemicals Limited | 529.13 Million INR | -5.739% |
| Caplin Point Laboratories Limited | 9.2 Billion INR | 93.923% |
| Shilpa Medicare Limited | 3.56 Billion INR | 84.292% |
| Valiant Laboratories Limited | 138.02 Million INR | -305.352% |
| Ajanta Pharma Limited | 21.06 Billion INR | 97.344% |
| Aarey Drugs & Pharmaceuticals Limited | 113.02 Million INR | -395.008% |
| Granules India Limited | 16.79 Billion INR | 96.669% |
| Medicamen Biotech Limited | 495.49 Million INR | -12.918% |
| Piramal Enterprises Limited | 8.04 Billion INR | 93.044% |
| Torrent Pharmaceuticals Limited | 46.75 Billion INR | 98.803% |
| NATCO Pharma Limited | 25.73 Billion INR | 97.826% |
| Suven Life Sciences Limited | -200.79 Million INR | 378.641% |
| Krebs Biochemicals & Industries Limited | -108.74 Million INR | 614.5% |
| Strides Pharma Science Limited | 14.38 Billion INR | 96.111% |
| Indoco Remedies Limited | 8.04 Billion INR | 93.044% |
| Alpa Laboratories Limited | 188.89 Million INR | -196.198% |
| Lasa Supergenerics Limited | 121.02 Million INR | -362.285% |
| Sun Pharma Advanced Research Company Limited | 391.06 Million INR | -43.071% |